Elizabeth Holmes went to prison. Her fraud did not.

Holmes is serving 11 years at a federal camp in Bryan, Texas, for defrauding investors out of hundreds of millions with Theranos, the blood-testing company that claimed it could run 200 tests on a single finger-prick. It could not. The machines produced garbage results, and real patients got real diagnoses based on that garbage. She trends again in 2026 because her partner, Billy Evans, is now raising money for a startup called Haemanthus that wants to test blood using lasers and AI. Same music, new instruments.

Here is why this should bother a nurse or a lab tech more than a venture capitalist. The Theranos scandal was not just rich people losing money. Walgreens put those broken machines in 40 stores in Arizona. Ordinary people walked in, gave blood, and trusted the number that came back. Theranos voided or corrected tens of thousands of test results. If your doctor tells you your potassium is fine when it is not, you can die. That is the actual stakes of a “disruptive” diagnostics pitch.

The pattern that keeps working: promise to replace a slow, boring, regulated process with a magic box and a charismatic founder. In 2015 the magic was microfluidics. In 2026 it is “AI.” Slap those two letters on anything and the checkbook opens. Haemanthus reportedly targeted a $50 million raise. Investors know the Holmes story. They are considering it anyway.

The counterargument is fair: Evans is not Holmes, and a new company deserves to prove itself on its own science. True. But the burden of proof for anything touching your bloodstream should be brutal, and “trust the founder’s vision” is exactly the sales script that turned Theranos into a crime scene.

The lesson for the rest of us is simple. When a health tech pitch leans on a personality instead of a peer-reviewed study, treat the personality as a warning light. Ask for the data. Ask who reviewed it. If the answer is a vibe and a laser, keep your finger, and your blood, to yourself.